Spero Therapeutics (SPRO) Competitors $1.91 -0.07 (-3.54%) Closing price 04:00 PM EasternExtended Trading$1.96 +0.05 (+2.36%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. RZLT, ORKA, PGEN, TERN, SIGA, PRTC, GOSS, CGEM, SVRA, and SNDLShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Rezolute (RZLT), Oruka Therapeutics (ORKA), Precigen (PGEN), Terns Pharmaceuticals (TERN), Siga Technologies (SIGA), PureTech Health (PRTC), Gossamer Bio (GOSS), Cullinan Therapeutics (CGEM), Savara (SVRA), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors Rezolute Oruka Therapeutics Precigen Terns Pharmaceuticals Siga Technologies PureTech Health Gossamer Bio Cullinan Therapeutics Savara SNDL Spero Therapeutics (NASDAQ:SPRO) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk. Is SPRO or RZLT more profitable? Rezolute has a net margin of 0.00% compared to Spero Therapeutics' net margin of -110.35%. Rezolute's return on equity of -70.09% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics-110.35% -120.27% -55.61% Rezolute N/A -70.09%-63.08% Do institutionals & insiders hold more shares of SPRO or RZLT? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 5.5% of Spero Therapeutics shares are held by insiders. Comparatively, 18.4% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, SPRO or RZLT? Rezolute has lower revenue, but higher earnings than Spero Therapeutics. Rezolute is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$47.98M2.24-$68.57M-$1.28-1.49RezoluteN/AN/A-$68.46M-$1.15-5.65 Does the media favor SPRO or RZLT? In the previous week, Spero Therapeutics had 6 more articles in the media than Rezolute. MarketBeat recorded 9 mentions for Spero Therapeutics and 3 mentions for Rezolute. Rezolute's average media sentiment score of 1.74 beat Spero Therapeutics' score of 0.73 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Rezolute 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate SPRO or RZLT? Spero Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 161.78%. Rezolute has a consensus target price of $12.20, indicating a potential upside of 87.69%. Given Spero Therapeutics' higher probable upside, equities analysts clearly believe Spero Therapeutics is more favorable than Rezolute.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Rezolute 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has more volatility & risk, SPRO or RZLT? Spero Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. SummaryRezolute beats Spero Therapeutics on 10 of the 16 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.43M$3.11B$5.67B$9.83BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-1.9520.3830.5825.12Price / Sales2.24367.51464.55116.64Price / CashN/A42.3037.4059.05Price / Book3.298.659.096.18Net Income-$68.57M-$54.65M$3.25B$264.89M7 Day Performance-12.79%6.59%4.76%2.66%1 Month Performance-23.29%9.57%6.72%3.05%1 Year Performance57.85%14.06%30.51%25.05% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.0498 of 5 stars$1.91-3.5%$5.00+161.8%+62.3%$111.43M$47.98M-1.95150Earnings ReportRZLTRezolute3.2075 of 5 stars$5.90+0.5%$11.83+100.6%+48.5%$510.67MN/A-5.1340ORKAOruka Therapeutics2.9321 of 5 stars$14.30+5.1%$40.38+182.3%N/A$509.19MN/A-3.17N/ANews CoverageEarnings ReportAnalyst ForecastAnalyst RevisionPGENPrecigen3.8769 of 5 stars$1.76+5.4%$6.00+240.9%+65.2%$492.95M$3.92M-3.14190Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap UpTERNTerns Pharmaceuticals4.0274 of 5 stars$5.75+5.1%$15.63+171.7%+4.3%$477.73MN/A-5.2840SIGASiga Technologies2.1162 of 5 stars$6.65+2.9%N/A-28.3%$461.51M$138.72M9.9340PRTCPureTech Health2.7806 of 5 stars$18.88-1.1%$45.00+138.3%-24.7%$458.62M$4.83M0.00100News CoverageShort Interest ↓Gap UpGOSSGossamer Bio3.8987 of 5 stars$2.17+8.5%$8.25+280.2%+137.0%$454.60M$114.70M-9.43180High Trading VolumeCGEMCullinan Therapeutics1.6812 of 5 stars$7.94+3.5%$30.00+277.8%-53.3%$452.64MN/A-2.7330SVRASavara2.9914 of 5 stars$2.57-0.8%$5.60+117.9%-29.3%$447.65MN/A-5.3520Trending NewsEarnings ReportAnalyst UpgradeGap UpSNDLSNDL2.2232 of 5 stars$1.64-0.6%$4.00+143.9%-2.3%$433.58M$671.81M-6.072,516Options Volume Related Companies and Tools Related Companies Rezolute Alternatives Oruka Therapeutics Alternatives Precigen Alternatives Terns Pharmaceuticals Alternatives Siga Technologies Alternatives PureTech Health Alternatives Gossamer Bio Alternatives Cullinan Therapeutics Alternatives Savara Alternatives SNDL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access